Identification of Circulating MicroRNA Signatures in Crohn's Disease Using the Nanostring nCounter Technology
Current clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activi...
Saved in:
Published in | Inflammatory bowel diseases Vol. 22; no. 9; pp. 2063 - 2069 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Oxford University Press
01.09.2016
|
Subjects | |
Online Access | Get full text |
ISSN | 1078-0998 1536-4844 1536-4844 |
DOI | 10.1097/MIB.0000000000000883 |
Cover
Abstract | Current clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.MethodsTo test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey–Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey–Bradshaw index.ResultsWe identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.ConclusionsCirculating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities. |
---|---|
AbstractList | BackgroundCurrent clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.MethodsTo test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey–Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey–Bradshaw index.ResultsWe identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.ConclusionsCirculating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities. Background: Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients. Methods: To test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey-Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey-Bradshaw index. Results: We identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement. Conclusions: Circulating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities. Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.BACKGROUNDCurrent clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.To test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey-Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey-Bradshaw index.METHODSTo test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey-Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey-Bradshaw index.We identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.RESULTSWe identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.Circulating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities.CONCLUSIONSCirculating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities. Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients. To test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey-Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey-Bradshaw index. We identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement. Circulating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities. Current clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative methods including imaging modalities and laboratory markers, such as C-reactive protein (CRP), are routinely applied to assess disease activity. However, laboratory markers poorly reflect the actual disease activity. Consequently, novel biomarkers represent a clinical necessity for CD patient management. We hypothesized that circulating serum-derived microRNAs may be used as diagnosis and disease activity monitoring tools of CD patients.MethodsTo test this hypothesis, we performed microRNA expression profiling through Nanostring nCounter technology in blood serum samples of CD patients and healthy control subjects. Harvey–Bradshaw index score was used to capture clinical disease activity; CRP was measured as part of standard clinical practice. The expression profile of circulating microRNAs and the levels of CRP correlated with Harvey–Bradshaw index.ResultsWe identified a signature of 10 circulating microRNAs that are differentially expressed in CD patients compared with healthy control subjects. Two of these microRNAs (hsa-miR-1286 and hsa-miR-1273d) correlated with CD disease activity and exhibited higher correlation values compared with CRP. Further analysis revealed distinct microRNA signatures between CD patients with ileal and colonic involvement.ConclusionsCirculating microRNAs show superior value as diagnostic and disease activity markers in comparison to traditional methods. Circulating microRNAs could improve CD patient management, if applied in combination with current state-of-the-art diagnostic and disease activity assessment modalities. |
Author | Hommes, Daniel W. Iliopoulos, Dimitrios Oikonomopoulos, Angelos Joshi, Swapna Polytarchou, Christos |
Author_xml | – sequence: 1 givenname: Angelos surname: Oikonomopoulos fullname: Oikonomopoulos, Angelos organization: Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California – sequence: 2 givenname: Christos surname: Polytarchou fullname: Polytarchou, Christos organization: †College of Arts and Science, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom – sequence: 3 givenname: Swapna surname: Joshi fullname: Joshi, Swapna organization: ‡Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California – sequence: 4 givenname: Daniel W. surname: Hommes fullname: Hommes, Daniel W. organization: Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California – sequence: 5 givenname: Dimitrios surname: Iliopoulos fullname: Iliopoulos, Dimitrios email: diliopoulos@mednet.ucla.edu organization: ‡Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27542126$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkctuFDEQRS0URB7wBwhZYgGbTvzsttmF5jVSEiRI1i3Hrp5x1GNPbPcif4-HCQjNhrgWdknnllX3HqODEAMg9JqSU0p0d3a5-HhK_j1K8WfoiEreNkIJcVDfpFMN0VodouOc7whhtfQLdMg6KRhl7RFaLxyE4kdvTfEx4Dji3ic7T7UNS3zpbYo_rs7xT78MpswJMvYB9ymuwruMP_kMJgO-yVu4rABfmRBzSds29HEOBRK-BrsKcYrLh5fo-WimDK8e7xN08-Xzdf-tufj-ddGfXzRWSFEaMEZxIYzstKNyFMZx4J3UsusEMMGts7dsVEwTyplyVPMOnFLOUTcqKQ0_Qe93czcp3s-Qy7D22cI0mQBxzgNVreKUay2fgFKmqrWirejbPfQuzinURQZOW60oYUJU6s0jNd-uwQ2b5NcmPQx_PK-A2AHV2pwTjH8RSoZttEONdtiPtso-7MmsL79DK8n46X_is504zpunffcLInSz1Q |
CitedBy_id | crossref_primary_10_1038_s41598_018_35876_5 crossref_primary_10_3389_fimmu_2022_865777 crossref_primary_10_1007_s00604_024_06405_1 crossref_primary_10_1038_s41598_019_45570_9 crossref_primary_10_1159_000511641 crossref_primary_10_1159_000515522 crossref_primary_10_18632_aging_202428 crossref_primary_10_3389_fphar_2022_813659 crossref_primary_10_1021_acsnano_7b04878 crossref_primary_10_18632_aging_101199 crossref_primary_10_1016_j_bbcan_2017_06_005 crossref_primary_10_1093_gastro_goab056 crossref_primary_10_1007_s40291_020_00447_w crossref_primary_10_1038_cddis_2017_440 crossref_primary_10_1002_lom3_10594 crossref_primary_10_1093_ecco_jcc_jjz120 crossref_primary_10_1007_s40291_017_0298_4 crossref_primary_10_3390_ijms20153662 crossref_primary_10_1053_j_gastro_2021_03_050 crossref_primary_10_1021_acssensors_9b00752 crossref_primary_10_3389_fonc_2023_1288077 crossref_primary_10_3389_fendo_2022_888948 crossref_primary_10_1016_j_exger_2017_06_017 crossref_primary_10_2217_epi_2016_0155 |
Cites_doi | 10.1016/S0140-6736(07)60750-8 10.1073/pnas.0804549105 10.1016/S0140-6736(12)60026-9 10.1097/MOG.0000000000000081 10.1038/nrgastro.2015.34 10.1053/j.gastro.2010.11.058 10.1136/gut.27.7.809 10.1097/01.MIB.0000173271.18319.53 10.1136/gut.30.9.1236 10.1016/j.cell.2011.10.043 10.1053/j.gastro.2013.07.001 10.1097/MIB.0000000000000547 10.1016/j.crohns.2014.02.012 10.1371/journal.pone.0031241 10.1200/JCO.2012.46.1558 10.1016/S0140-6736(12)60150-0 10.1016/j.crohns.2012.02.006 10.1371/journal.pone.0140155 10.1016/S0140-6736(80)92767-1 10.1097/MPG.0b013e31822200cc 10.1002/ibd.21695 10.1053/j.gastro.2008.07.068 10.1053/j.gastro.2015.05.057 10.1002/ibd.21450 10.1111/j.1349-7006.2010.01650.x 10.1111/cei.12104 10.1038/nrd3864 10.1016/j.trsl.2012.01.001 10.1080/00365520500320094 10.1097/MIB.0b013e3182810066 10.1038/ni.f.209 10.1111/j.1572-0241.2008.02158.x 10.1097/01.MIB.0000436954.70596.9b 10.1371/journal.pone.0013160 |
ContentType | Journal Article |
Copyright | Copyright © 2016 Crohn's & Colitis Foundation of America, Inc. 2016 Copyright © 2016 Crohn's & Colitis Foundation of America, Inc. |
Copyright_xml | – notice: Copyright © 2016 Crohn's & Colitis Foundation of America, Inc. 2016 – notice: Copyright © 2016 Crohn's & Colitis Foundation of America, Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7T5 H94 |
DOI | 10.1097/MIB.0000000000000883 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central - New (Subscription) ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
DatabaseTitleList | ProQuest One Academic Middle East (New) AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1536-4844 |
EndPage | 2069 |
ExternalDocumentID | 27542126 10_1097_MIB_0000000000000883 10.1097/MIB.0000000000000883 |
Genre | Journal Article |
GroupedDBID | --- .Z2 0R~ 1OC 3WU 48X 53G 5GY 5VS 5WD 66C 7O~ 8-0 8UM AAAXR AABZA AACZT AAKAS AAPQZ AAPXW AARHZ AARTV AAUAY AAVAP AAYEP ABBUW ABDFA ABEJV ABGNP ABJNI ABNHQ ABOCM ABPQP ABPTD ABQNK ABVGC ABWST ABXVJ ABXVV ABZAD ACDDN ACEWG ACGFO ACGFS ACUTJ ACWDW ACWRI ACXNZ ACYHN ADBBV ADBIZ ADGZP ADIPN ADQBN ADRTK ADVEK ADZCM AENEX AETBJ AFFZL AFOFC AFTRI AFUWQ AFXAL AGINJ AGQXC AGUTN AHMBA AHMMS AIJEX AIZYK AJEEA ALMA_UNASSIGNED_HOLDINGS ATGXG AWKKM BAYMD BCRHZ BEYMZ BOYCO BTRTY C45 CDBKE CS3 DAKXR DR2 DU5 E.X E3Z EBS EJD ENERS EX3 F5P FECEO FL- FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H0~ HZ~ IN~ IX1 KBUDW KOP KSI KSN LAW MHKGH NNB NOMLY NOYVH NVLIB N~7 N~B O9- OAUYM OCZFY ODMLO OIG OJZSN OPAEJ OVD OWPYF P2P PAFKI PQQKQ QRW ROX RUSNO RX1 S4S TEORI V2E WOW XV2 YAYTL YKOAZ YXANX ZFV 31~ 4.4 7X7 8-1 88E 8F7 8FI 8FJ AAJQQ AAPGJ AAUQX AAWDT AAYXX ABUWG ACFRR ACVCV ACXQS ACZBC ADMTO ADNBA AEMQT AFBPY AFFQV AFKRA AFYAG AFZJQ AGKRT AGMDO AGORE AHGBF AHRYX AJAOE AJBYB AJDVS AJNCP AJNYG ALXQX APJGH AQDSO AQKUS AVNTJ BENPR CCPQU CITATION EIHJH FYUFA H13 HMCUK IAO IHR ITC JXSIZ LH4 LW6 M1P MBLQV NU- OBFPC OCUKA ORVUJ PHGZM PHGZT PSQYO ROL TMA UKHRP W99 WOQ Y6R CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS PUEGO 7X8 7T5 H94 |
ID | FETCH-LOGICAL-c454t-eaa8344a579d15f4ad3e37595774e243cdcb2f82901328d1937ed88dd1df855a3 |
IEDL.DBID | 7X7 |
ISSN | 1078-0998 1536-4844 |
IngestDate | Mon Sep 08 17:30:59 EDT 2025 Mon Sep 08 11:31:09 EDT 2025 Fri Sep 19 20:56:17 EDT 2025 Wed Feb 19 02:43:12 EST 2025 Tue Jul 01 04:19:54 EDT 2025 Thu Apr 24 23:00:15 EDT 2025 Sat Feb 08 08:13:05 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | serum microRNAs Crohn's disease blood biomarkers circulating microRNAs |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c454t-eaa8344a579d15f4ad3e37595774e243cdcb2f82901328d1937ed88dd1df855a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://academic.oup.com/ibdjournal/article-pdf/22/9/2063/23404634/ibd2063.pdf |
PMID | 27542126 |
PQID | 3169810244 |
PQPubID | 996336 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1868313995 proquest_miscellaneous_1812888346 proquest_journals_3169810244 pubmed_primary_27542126 crossref_primary_10_1097_MIB_0000000000000883 crossref_citationtrail_10_1097_MIB_0000000000000883 oup_primary_10_1097_MIB_0000000000000883 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-09-01 |
PublicationDateYYYYMMDD | 2016-09-01 |
PublicationDate_xml | – month: 09 year: 2016 text: 2016-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: United States – name: Baltimore |
PublicationTitle | Inflammatory bowel diseases |
PublicationTitleAlternate | Inflamm Bowel Dis |
PublicationYear | 2016 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Ananthakrishnan (R4-3-20160819) 2015; 12 Solem (R11-3-20160819) 2005; 11 Baltimore (R17-3-20160819) 2008; 9 Duttagupta (R28-3-20160819) 2012; 7 Iskandar (R8-3-20160819) 2012; 159 Polytarchou (R22-3-20160819) 2015; 21 Zahm (R33-3-20160819) 2011; 53 Sincic (R3-3-20160819) 2006; 41 Ordas (R35-3-20160819) 2012; 380 Thia (R2-3-20160819) 2008; 103 Wu (R20-3-20160819) 2008; 135 Chuang (R30-3-20160819) 2014; 20 Dowsett (R23-3-20160819) 2013; 31 van Rooij (R16-3-20160819) 2012; 11 Paraskevi (R26-3-20160819) 2012; 6 Crama-Bohbouth (R7-3-20160819) 1989; 30 Jussila (R6-3-20160819) 2012; 18 Saverymuttu (R10-3-20160819) 1986; 27 Wu (R32-3-20160819) 2011; 17 Koukos (R19-3-20160819) 2013; 145 Zahm (R31-3-20160819) 2014; 8 Schoepfer (R12-3-20160819) 2013; 19 Cho (R15-3-20160819) 2010; 1805 Baumgart (R1-3-20160819) 2007; 369 Hubenthal (R29-3-20160819) 2015; 10 Kosaka (R14-3-20160819) 2010; 101 Li (R24-3-20160819) 2015; 2015 Baumgart (R34-3-20160819) 2012; 380 Lewis (R9-3-20160819) 2011; 140 Mitchell (R13-3-20160819) 2008; 105 Fasseu (R27-3-20160819) 2010; 5 Polytarchou (R36-3-20160819) 2014; 30 Harvey (R5-3-20160819) 1980; 315 Hatziapostolou (R18-3-20160819) 2011; 147 Polytarchou (R21-3-20160819) 2015; 149 Iborra (R25-3-20160819) 2013; 173 |
References_xml | – volume: 369 start-page: 1627 year: 2007 ident: R1-3-20160819 publication-title: Lancet doi: 10.1016/S0140-6736(07)60750-8 – volume: 105 start-page: 10513 year: 2008 ident: R13-3-20160819 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0804549105 – volume: 380 start-page: 1590 year: 2012 ident: R34-3-20160819 publication-title: Lancet doi: 10.1016/S0140-6736(12)60026-9 – volume: 30 start-page: 339 year: 2014 ident: R36-3-20160819 publication-title: Curr Opin Gastroenterol doi: 10.1097/MOG.0000000000000081 – volume: 12 start-page: 205 year: 2015 ident: R4-3-20160819 publication-title: Nat Reviews Gastroenterol Hepatol doi: 10.1038/nrgastro.2015.34 – volume: 140 start-page: 1817 year: 2011 ident: R9-3-20160819 publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.11.058 – volume: 27 start-page: 809 year: 1986 ident: R10-3-20160819 publication-title: Gut doi: 10.1136/gut.27.7.809 – volume: 11 start-page: 707 year: 2005 ident: R11-3-20160819 publication-title: Inflamm Bowel Dis doi: 10.1097/01.MIB.0000173271.18319.53 – volume: 30 start-page: 1236 year: 1989 ident: R7-3-20160819 publication-title: Gut doi: 10.1136/gut.30.9.1236 – volume: 147 start-page: 1233 year: 2011 ident: R18-3-20160819 publication-title: Cell doi: 10.1016/j.cell.2011.10.043 – volume: 145 start-page: 842 year: 2013 ident: R19-3-20160819 publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.07.001 – volume: 21 start-page: 2533 year: 2015 ident: R22-3-20160819 publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000547 – volume: 2015 start-page: 524519 year: 2015 ident: R24-3-20160819 publication-title: Biomed Res Int – volume: 8 start-page: 1108 year: 2014 ident: R31-3-20160819 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2014.02.012 – volume: 7 start-page: e31241 year: 2012 ident: R28-3-20160819 publication-title: PLoS One doi: 10.1371/journal.pone.0031241 – volume: 31 start-page: 2783 year: 2013 ident: R23-3-20160819 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.46.1558 – volume: 380 start-page: 1606 year: 2012 ident: R35-3-20160819 publication-title: Lancet doi: 10.1016/S0140-6736(12)60150-0 – volume: 6 start-page: 900 year: 2012 ident: R26-3-20160819 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2012.02.006 – volume: 10 start-page: e0140155 year: 2015 ident: R29-3-20160819 publication-title: PLoS One doi: 10.1371/journal.pone.0140155 – volume: 315 start-page: 514 year: 1980 ident: R5-3-20160819 publication-title: Lancet doi: 10.1016/S0140-6736(80)92767-1 – volume: 53 start-page: 26 year: 2011 ident: R33-3-20160819 publication-title: J Pediatr Gastroenterol Nutr doi: 10.1097/MPG.0b013e31822200cc – volume: 18 start-page: 555 year: 2012 ident: R6-3-20160819 publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.21695 – volume: 135 start-page: 1624 year: 2008 ident: R20-3-20160819 publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.07.068 – volume: 149 start-page: 981 year: 2015 ident: R21-3-20160819 publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.05.057 – volume: 17 start-page: 241 year: 2011 ident: R32-3-20160819 publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.21450 – volume: 101 start-page: 2087 year: 2010 ident: R14-3-20160819 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2010.01650.x – volume: 173 start-page: 250 year: 2013 ident: R25-3-20160819 publication-title: Clin Exp Immunol doi: 10.1111/cei.12104 – volume: 1805 start-page: 209 year: 2010 ident: R15-3-20160819 publication-title: Biochim Biophys Acta – volume: 11 start-page: 860 year: 2012 ident: R16-3-20160819 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3864 – volume: 159 start-page: 313 year: 2012 ident: R8-3-20160819 publication-title: Transl Res doi: 10.1016/j.trsl.2012.01.001 – volume: 41 start-page: 437 year: 2006 ident: R3-3-20160819 publication-title: Scand J Gastroenterol doi: 10.1080/00365520500320094 – volume: 19 start-page: 332 year: 2013 ident: R12-3-20160819 publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0b013e3182810066 – volume: 9 start-page: 839 year: 2008 ident: R17-3-20160819 publication-title: Nat Immunol doi: 10.1038/ni.f.209 – volume: 103 start-page: 3167 year: 2008 ident: R2-3-20160819 publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2008.02158.x – volume: 20 start-page: 126 year: 2014 ident: R30-3-20160819 publication-title: Inflamm Bowel Dis doi: 10.1097/01.MIB.0000436954.70596.9b – volume: 5 start-page: e13160 year: 2010 ident: R27-3-20160819 publication-title: PLoS One doi: 10.1371/journal.pone.0013160 |
SSID | ssj0020209 |
Score | 2.32722 |
Snippet | Current clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative... Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD). Alternative... BackgroundCurrent clinical indices, such as Harvey–Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD).... Background: Current clinical indices, such as Harvey-Bradshaw index, are often inadequate for the assessment of disease activity in Crohn's disease (CD).... |
SourceID | proquest pubmed crossref oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2063 |
SubjectTerms | Adult Biomarkers - blood C-Reactive Protein - analysis Case-Control Studies Circulating MicroRNA - blood Circulating MicroRNA - genetics Colon - metabolism Crohn Disease - blood Crohn Disease - diagnosis Crohn Disease - genetics Crohn's disease Female Gene Expression Profiling - methods Humans Ileum - metabolism Male MicroRNAs Middle Aged Nucleic Acid Hybridization - methods Patients |
Title | Identification of Circulating MicroRNA Signatures in Crohn's Disease Using the Nanostring nCounter Technology |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27542126 https://www.proquest.com/docview/3169810244 https://www.proquest.com/docview/1812888346 https://www.proquest.com/docview/1868313995 |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFD5sLYy9lO6etSsaDLYX0dm6WH4abdrSDRJGtkLejKxLF2jtNk7__44sOaEbdPObsCyLo9t3bvoAPhipfcHymtaKl5Qz5WnJpKOyqE3mlPCmTxSeTOX5Bf82F_NkcOtSWOWwJ_YbtW1NsJEfskyWCk9Dzr_c3NLAGhW8q4lC4zFsZ4hEAnVDMd8oXJ9jiAdqOMHFX6ohda4sDidfj-PVhcOjFLt3NN1Ld_sLdfanz9ku7CTYSI7iOD-DR655Dk8myTH-Aq5jwq1PFjjSejJeLE3PzdVckkkIu5tNj8iPxWW8yrMji4aMl-2v5mNHTqKXhvTxAwQhIcFNtw2MHlhsQto6Sp9srPAv4eLs9Of4nCYmBWq44CvqtA58GloUpc2E59oyxwpRCgR_LufMWFPnvvepslxZFGXhrFLWZtYrITR7BVtN27g3QLSxtSlRz7K2xhYN4t1cGu81arv4MzYCNgixMuma8cB2cVUN7m4UffWn6EdA11_dxGs2_lH_E47Pf1bdHwaxSuuzqzazaQTv169xZQV3iW5ce9dVAfsobIDLh-pIxbKQHjyC13GCrDuVB3LhLJdvH-7AHjxFECZj3No-bK2Wd-4dAp1VfdDP5gPYPj6dfp9h6WSW_wbRd_cf |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgGXijdbChgJBBerxI_EOVSobKl2abMHaKW9pYkfZSVIymYrxJ_iN3YcJ7sqSIVLc4viONHMeDzjeXwAr3RcuISzkpZKpFRw5WjKY0vjpNSRVdLptlA4m8SjY_FpKqdr8LuvhfFplb1ObBW1qbU_I9_mUZwq3A2FeH_2g3rUKB9d7SE0glgc2F8_0WVrdsZ7yN_XjO1_PBqOaIcqQLWQYkFtUXhsiUImqYmkE4XhlicylWgIWSa4Nrpkro0vcqYMGjiJNUoZExmnpCw4znsDbgofYsT1k0xXDt67kFKCHpVPKUhVX6qXJtvZ-ENoldhfSvFLW-Gl8rq_rNx2t9u_CxudmUp2g1zdgzVb3YdbWReIfwDfQ4Gv6078SO3IcDbXLRZYdUoyn-b3ebJLvsxOQ-vQhswqMpzXX6s3DdkLUSHS5isQNEEJKvnaI4jgbeXL5JHbZHXq_xCOr4XGj2C9qiv7BEihTalT9OuMKXFGjfY1i7VzBXrX-DE-AN4TMdddW3OPrvEt78PrSPr8T9IPgC7fOgttPf4x_i3y5z-HbvVMzDt90OQr6R3Ay-VjXMk-PFNUtj5vcm9rKZxAxFeNiRWPfDnyAB4HAVn-FPNgxhGLN6_-gRdwe3SUHeaH48nBU7jDPJ5xm368BeuL-bl9hkbWonzeSjaBk-teShd_IzEg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+Circulating+MicroRNA+Signatures+in+Crohn%27s+Disease+Using+the+Nanostring+nCounter+Technology&rft.jtitle=Inflammatory+bowel+diseases&rft.au=Oikonomopoulos%2C+Angelos&rft.au=Polytarchou%2C+Christos&rft.au=Joshi%2C+Swapna&rft.au=Hommes%2C+Daniel+W&rft.date=2016-09-01&rft.eissn=1536-4844&rft.volume=22&rft.issue=9&rft.spage=2063&rft_id=info:doi/10.1097%2FMIB.0000000000000883&rft_id=info%3Apmid%2F27542126&rft.externalDocID=27542126 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0998&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0998&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0998&client=summon |